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Abstract: The purpose of this pilot study was to correlate the three biologic markers of the 
Ovulon fertility monitor (a long-term predictive peak about 6 days before ovulation, a short-term 
predictive peak about 1 day before ovulation, and a nadir at the time of ovulation) with the peak 
in cervical mucus and the luteinizing hormone (LH) surge in the urine. Ten volunteer subjects 
(mean age 30.2 years) monitored their cervical-vaginal mucus, the surge of LH in the urine with a 
home assay test, and their vaginal electrical readings (with Ovulon monitors) on a daily basis for 
one to four menstrual cycles. In 19 of the 21 cycles that indicated a LH surge, there was a strong 
positive correlation between the LH surge and the peak of cervical-vaginal mucus (r = 0.96, P 
≤ .01), and between the LH surge and both the Ovulon nadir and Ovulon short-term predictive 
peak (r = 0.84, P ≤ .01), and a modest positive correlation between the long-term Ovulon 
predictive peak and the LH surge (r = 0.62, P ≤ .01). The time of optimal fertility as determined by 
the peak in cervical mucus, the LH surge, and the Ovulon was similar. The Ovulon has potential 
as a reusable device to help women determine their fertile period.  
 
The ability to predict and detect ovulation is critical for women who wish to achieve or 
avoid pregnancy. The most common methods of predicting ovulation in use today are monitored 
basal body temperature (BBT), self-observation of cervical-vaginal mucus, and self-testing of 
luteinizing hormone (LH) in the urine. All three of these methods have advantages and 
disadvantages. In recent years, a number of technological devices have been developed to help 
women determine their optimal time of fertility. This technology is important for women who are 
trying to achieve or avoid pregnancy. The devices include electronic and computerized BBT, 
hormonal test kits, cervical-vaginal fluid volume meters, and crystallization monitors (1).  
A recently developed device to aid in the prediction and detection of ovulation is the 
Ovulon fertility monitor (Conception Technology Inc.; Fort Collins, CO). The Ovulon prototype 
consists of a hand-held digital monitor and a vaginal sensor that is inserted like a tampon, for 
about 30 seconds, on a daily basis (Figure 1). The vaginal sensor harmlessly detects 
bioelectrical measurements. The measurements are harmless because of two design features: 
1) the biocompatible (carbonaceous) material of the active elements cannot release any harmful 
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or potentially harmful substances into the vagina and 2) the electrical mode of measurement is 
such that no electrical energy is passed into the body and no electrochemical reactions 
(electrolysis) can occur.  
The device is based on the changes in electrical admittance as a result of the sensitivity 
of the cervical tissues to steroid hormones such as preovulatory estrogen that stimulate the 
production of and changes in cervical epithelium and mucus. The electrical changes are 
theoretically produced by the oxidative-reduction reactions that take place in the mucus 
glycoproteins of the cervical mucus. The electron transfer reactions in the biologic material 
interact with the electronic structure of the active elements, and the interaction is detected by the 
measured admittance.  
The OvuIon monitor can be used to both predict and confirm ovulation. The Ovulon 
monitor produces three biologic markers: a long-term predictive peak in electrical admittance 
about 5-7 days before ovulation, a second short-term peak about 1 day before ovulation, and a 
nadir of electrical admittance on the day of ovulation.  
A device superficially similar to the Ovulon, the CUE fertility monitor, was developed by 
the Zetek Corporation (Aurora, CO) (2-4). Unlike the Ovulon, the CUE monitor uses both a 
salivary and vaginal sensor and is based on ionic conductivity as a result of 
aldosterone-stimulated concentrations of salt and water in the cervical mucus and saliva.  
The Ovulon monitor has never been widely tested. Dr. Benedetto of the University of 
Torino Institute of Obstetrics and Gynecology tested an early model of the Ovulon with four 
young healthy women and reported in an unpublished study that they were all able to 
demonstrate a long-term predictive peak before the ovulation marker of the instrument and a 
short-term predictive peak about the day before ovulation, except for one case where a probable 
luteal phase defect was associated with the absence of the predictive peaks. Further study of the 
Ovulon monitor needs to take place to determine its applicability for family planning.  
One method of determining the Ovulon's accuracy in detecting the fertile period is to 
compare it with other standard markers of ovulation. Two commonly accepted and researched 
methods of detecting ovulation are the self-observation of cervical-vaginal mucus and the 
self-detection of LH in the urine. The detection of LH in plasma or urine is considered by experts 
to be a standard method to predict ovulation (5,6). Manufacturers of ovulation tests kits claim a 
greater than 90% accuracy in detecting the urine LH surge, which occurs about 12-24 hours 
before ovulation (7,8). Optimal or "peak" cervical-vaginal mucus (defined as mucus that 
stretches 2.5 cm or more, is clear on appearance, and/or has the sensation of lubrication) as 
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obtained from the vaginal opening also correlates closely with the day of ovulation and the day of 
the LH surge (9,10). The specific aim of this pilot study was to determine the accuracy of the 
Ovulon fertility monitor by comparing and correlating the peak in cervical mucus and the LH 
surge in the urine with the three biologic markers of the Ovulon monitor.  
 
Methodology 
Ten volunteer female subjects (mean age 30.2 years) with regular menstrual cycles (ie, 
cycles of 21-38 days in length) who were trained in the use of the Creighton model ovulation 
method of natural family planning (NFP) (mean months of use 32.0) monitored their 
cervical-vaginal mucus, the surge of LH in the urine with the OvuQuick assay test, and their 
vaginal electrical/chemical readings (with the Ovulon monitor) on a daily basis for one to four 
menstrual cycles using 10 prototype Ovulon monitors.  
The LH surges in the urine were self-detected by use of the OvuQuick self-test kit. The 
OvuQuick is based on monoclonal enzyme immunoassay of LH in the urine. The test has a 
reported LH sensitivity of 30 mIU/mL. OvuQuick has shown a 98% agreement with other tests in 
detecting the LH surge (5).  
The peak day of cervical mucus was determined by means of the Creighton model 
vaginal discharge recording system (VDRS), developed through research conducted at St. Louis 
and Creighton Universities over a 5-year period (11). The recording system requires that women 
check for cervical-vaginal mucus by wiping the outside of their vaginas (the vulvar area) every 
time they go to the bathroom to void and once before going to bed. The women check mucus for 
color, stretch, and consistency. The VDRS has a reported 99% method effectiveness and a 95% 
use-effectiveness for determining fertile and nonfertile days of the cycle (11,12).  
An algorithm was developed to standardize the determination of the biologic markers of 
fertility asdetermined by the three methods, ie, the Ovulon monitor, the LH, and the 
cervical-vaginal mucus. The decision criteria for the Ovulon data are as follows:  
 
• LH-the last day of the LH surge as detected in the urine with the home 
test kit and recorded on the fertility chart.  
• P-the last day of mucus that was either clear on appearance, stretches an 
inch or more, and/or had the sensation of lubrication as observed by the 
subject and recorded on the fertility chart. 
• OS-the day of the highest Ovulon reading. "OS" stands for the short-term 
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Ovulon predictor (Figure 2). 
• OL-the day of the highest Ovulon reading preceding the OS. “OL” stands 
for the long-term Ovulon predictor. 
• O-the day of the lowest Ovulon reading after the OS.  
 
Using the above algorithm, interrater reliability was determined between the decision of 
the principal researcher and a graduate student research assistant on the day of the observed 
biologic markers. The interrater ratio of the observed day of LH, P, 0, and OS was 100% and the 
OL day was 90%.  
 
Results 
Nineteen of the 21 menstrual cycles indicated an LH surge (Table 1). In the 19 cycles 
with an established LH surge, there was a strong positive correlation between the LH surge in 
the urine and the peak day of cervical mucus (r = 0.96, P ≤ .01), between the LH surge and the 
Ovulon nadir "O" (r = 0.84, P ≤ .01), and between the LH surge and the Ovulon short-term 
predictive peak "OS" (r = 0.84, P ≤ .01). There was a modest positive correlation between the 
long-term Ovulon predictive peak "OL" and the LH surge (r = 0.62, P ≤ .01). There also was a 
strong positive correlation between the peak day of cervical mucus and the Ovulon nadir (r = 
0.86, P ≤ .01). In the 19 cycles in which an LH surge was detected, the Ovulon short-term 
predictive peak was within ± 3 days of the LH surge.  
 
Discussion 
Although the Ovulon monitor is based on a different technology than the CUE fertility 
monitor, the results of this study are similar to the strong correlation between the LH surge and 
the predicted day of ovulation (r = 0.79) found by Moreno et al. (4). The Ovulon's predicted day of 
ovulation "O" correlated positively with the LH surge (r = 0.84) and the peak in cervical mucus (r 
= 0.82). The conclusion, therefore, is that the Ovulon monitor has similar accuracy in predicting 
ovulation as the ovulation method of NFP, the urine LH detection kits, and the CUE fertility 
monitor. The short-term Ovulon ovulation predictor also had a strong correlation with the LH 
surge (r = 0.84) and the peak in cervical mucus (r = 0.86). The Ovulon short-term predictor 
ranged from 1 to 4 days with an average of 2.3 days before the Ovulon nadir. This short-term 
predictive peak would be especially beneficial for those women and couples trying to achieve 
pregnancy because fertility drops dramatically shortly after ovulation (13). The short-term 
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predictive peak would not give enough warning time for those wishing to avoid pregnancy.  
The long-term Ovulon marker, however, has potential for women and couples trying to 
avoid pregnancy. Except for one of the cycles, the OL to O period ranged from 4 to 11 days with 
an average of 7.2 days. This length is somewhat longer than the average length of the total fertile 
period (6 days) as defined by the ovulation method. The long-term Ovulon predictive peak only 
had a modest correlation with the LH surge (r = 0.61) and with the peak in cervical mucus (r = 
0.71). The conclusion is that at this time the OL is a very rough predictive marker of the 
beginning of the fertile period.  
A limitation of the study is that the Ovulon was only tested on a small number of healthy 
women who had relatively regular menstrual cycles. Also, the Ovulon monitors were prototype 
instruments. For the Ovulon to be useful as a family planning method further testing will need to 
take place with women with varying cyclic patterns (eg, postpartum, breastfeeding, infertile, long 
cycles) and with refined instruments. Another limitation of the study is that the LH surge in the 
urine and the peak day of cervical mucus are indirect tests of ovulation. Use of serial transvaginal 
ultrasonography would add more precision and validity to the study. The expense of serial 
ultrasonography was beyond the scope and budget of this study. A final limitation of this study is 
that Ovulon data from 5 cycles (ie, in cycle number 3.2, 8.1, 8.2, 9.1, and 10.2) were interpreted 
in light of the peak in cervical mucus rather than by strict adherence to the established algorithm. 
These were cycles with Ovulon profiles that deviated from the expected or baseline pattern for 
reasons that are not understood. The expectation is that a larger study with a variety of 
reproductive categories with a range of clinical and biochemical measurements will provide that 
understanding.  
Nurse-midwives and nurses have long incorporated teaching women about their body's 
physiology as part of educating women in self-care measures. Use of convenient, safe, and 
accurate devices to monitor physiologic process, such as a woman's fertility cycle, should be 
advocated. A benefit of the Ovulon monitor is that it is a reusable instrument, unlike the urine LH 
test kits that need to be purchased for each cycle. The Ovulon fertility monitor has potential to be 
a very useful device to assist nurse-midwives in fertility and infertility assessment, therapy, and 
family planning.  
 
Notes 
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Appendix 
Table 1 
Comparison of the Three Ovulon Biological Markers (O, OS, and OL) with the Day of the 
Luteinizing Hormone Surge and the Peak in Cervical Mucus  
 
Subject/Cycle Age (y) N/M LH Peak O OS OL 
1.1 35 M 17 17 16 14 11 
1.2   16 16 17 13 07 
2.1 33 M 14 14 17 15 12 
2.2   14 14 14 12 06 
3.1 42 M 13 13 14 13 12 
3.2   17 18 17 15 11 
4.1 33 N 13 13 15 13 07 
4.2   11 12 14 11 07 
5.1 30 M 19 20 20 18 12 
6.1 38 M 15 16 19 15 08 
6.2   15 16 18 15 08 
7.1 29 N 16 17 18 16 10 
7.2   14 13 15 14 08 
8.1 19 N 21 23 21 18 12 
8.2   - 21 24 21 14 
9.1 41 N 14 15 18 16 08 
9.2   13 14 13 12 09 
9.3   15 16 18 15 10 
9.4   14 13 15 13 07 
10.1 22 N - 09 12 10 07 
10.2   10 12 10 08 06 
 
N, nulliparous; M, multiparous.  
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Figure 1  
Prototype Ovulon fertility monitor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  
Ovulon baseline pattern with three biologic markers 
 
